Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Open Access Highly Accessed Research article

New autoantibodies in early rheumatoid arthritis

Caroline Charpin12, Fanny Arnoux1, Marielle Martin1, Eric Toussirot3, Nathalie Lambert1, Nathalie Balandraud12, Daniel Wendling3, Elisabeth Diot4, Jean Roudier12 and Isabelle Auger1*

Author affiliations

1 INSERM UMRs 1097, Aix Marseille Université, 163 Avenue de Luminy, 13288 Marseille, France

2 Rheumatology, IML, APHM, 270 Boulevard de Sainte Marguerite, 13009 Marseille, France

3 Service de Rhumatologie, CHU Jean Minjoz, 2 Boulevard Fleming, 25030 Besançon, France

4 Service de Médecine Interne, CHU Bretonneau, 2 Boulevard Tonnellé, 37000 Tours, France

For all author emails, please log on.

Citation and License

Arthritis Research & Therapy 2013, 15:R78  doi:10.1186/ar4255

Published: 25 July 2013

Abstract

Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease causing articular cartilage and bone destruction. Since irreversible joint destruction can be prevented by intervention at the early stages of disease, early diagnosis of RA is important. In this study, we identified new autoantibodies in the sera of patients with early (less than one year) RA.

Methods

We screened the sera of 20 RA patients with disease duration less than one year, 19 RA patients with disease duration more than five years and 23 controls on 8,268 human protein arrays. We confirmed the validity of protein array detection by ELISA assays. We then performed epitope mapping with overlapping 15-mers to analyze RA sera reactivity.

Results

WIBG (within BGCN homolog (Drosophila)), GABARAPL2 (GABA(A) receptor associated protein like 2) and ZNF706 (zinc finger protein 706) proteins are preferentially recognized by autoantibodies from early RA patients. Of interest, autoantibodies to WIBG are very specific for early RA. Indeed, 33% of early RA patients' sera recognize WIBG versus 5% of RA patients with disease duration more than 5 years and 2% of controls. We identified three linear peptides on WIBG GABARAPL2 and ZNF706 that are preferentially recognized by sera of early RA patients.

Conclusions

We identified new autoantibodies associated with RA with disease duration less than one year. These autoantibodies could be used as diagnosis markers in RA patients.

Keywords:
rheumatoid arthritis; autoantibodies; early biomarkers